Uncategorized
These Analysts Raise Their Forecasts On Boeing Following Q4 Results
Latest Ratings for BA Date Firm Action From To Mar 2022 Cowen & Co. Maintains Outperform Jan 2022 Jefferies Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for BA View the Latest Analyst Ratings read more
These Analysts Cut Their Forecasts On Polaris After Q4 Results
Latest Ratings for PII Date Firm Action From To Feb 2022 Citigroup Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight Jan 2022 Raymond James Maintains Strong Buy View More Analyst Ratings for PII View the Latest Analyst Ratings read more
Qorvo Analysts Slash Their Forecasts After Q3 Results
Latest Ratings for QRVO Date Firm Action From To Mar 2022 Morgan Stanley Downgrades Overweight Equal-Weight Feb 2022 Benchmark Maintains Buy Feb 2022 Mizuho Maintains Neutral View More Analyst Ratings for QRVO View the Latest Analyst Ratings read more
Teva Pharmaceutical Stock Falls On Q4 Earnings: What’s Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of 70 cents per share. read more
Deep Dive Into Dick’s Sporting Goods Stock: Analyst Perspectives (7 Ratings)
Latest Ratings for DKS Date Firm Action From To Mar 2022 Truist Securities Maintains Buy Mar 2022 Cowen & Co. Maintains Outperform Mar 2022 Stephens & Co. Maintains Equal-Weight View More Analyst Ratings for DKS View the Latest Analyst Ratings read more
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
Latest Ratings for GILD Date Firm Action From To Mar 2022 Barclays Maintains Underweight Mar 2022 RBC Capital Maintains Outperform Feb 2022 BMO Capital Downgrades Outperform Market Perform View More Analyst Ratings for GILD View the Latest Analyst Ratings read more